PPARG and Alzheimer disease: In mouse models of AD, LXR and RXR agonists ameliorate memory deficits and decrease the Aβ load due to the up-regulation of ApoE (Koldamova et al., 2005; Jiang et al., 2008; Fitz et al., 2010; Cramer et al., 2012), and the two PPARγ agonists used for the treatment of diabetes, Pioglitazone and Rosiglitazone, reduce Aβ levels and improve cognitive functions in AD mice (Mandrekar-Colucci and Landreth, 2011).